TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37965307

Group type: EXPERIMENTAL
Intervention: Prognostic model based on nine TME-related genes (TMRGs): C3orf62, DPYSL2, GZMA, SERPINB3, RHCG, PTPRR, STMN3, TMPRSS4, COMP.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMEscore for overall survival (OS) prediction.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-risk group characteristics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of TMEscore with drug susceptibility and immune cell infiltration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SERPINB3 gene expression.
Number of subjects: 0
Study: 37965339

Group type: EXPERIMENTAL
Intervention: T cell product specific for CMV and EBV, administered on day +30, total of 25 doses
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 9
Study: 37965347

Group type: EXPERIMENTAL
Intervention: ConA plus standard of care (SOC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 84
Study: 37965376

Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (n=17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham treatment (n=16)
Number of subjects: 33
Study: 37965431

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 37965466

Group type: EXPERIMENTAL
Intervention: Proton beam therapy (PBT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Photon-based radiation therapy (XRT)
Number of subjects: 99
Study: 37965628

Group type: EXPERIMENTAL
Intervention: Novel PCR-based approach for quantifying donor-derived cell-free DNA (dd-cfDNA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Blood samples collected coincidentally to biopsies
Number of subjects: 52
Study: 37965767

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (LPD)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (OPD)
Number of subjects: 656
Study: 37965771

Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine added to spinal anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal anesthesia without epinephrine (implied control)
Number of subjects: 0
Study: 37965944

Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus no treatment
Number of subjects: 2888

Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus watchful waiting
Number of subjects: 2888

Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus non-surgical treatment (antibiotics)
Number of subjects: 2888

Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus myringotomy
Number of subjects: 2888
Study: 37966076

Group type: EXPERIMENTAL
Intervention: Preoperative ostomy education intervention
Number of subjects: 138

Group type: COMPARATOR
Intervention: Postoperative education
Number of subjects: 138
Study: 37966080

Group type: EXPERIMENTAL
Intervention: Micro-hole drainage zone catheter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional eyelet catheter (CEC)
Number of subjects: 60
Study: 37966286

Group type: EXPERIMENTAL
Intervention: Arginine-stimulated copeptin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Hypertonic saline-stimulated copeptin
Number of subjects: 158
Study: 37966285

Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 1965

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1965
Study: 37966313

Group type: EXPERIMENTAL
Intervention: Cognitive and Emotional Responses to COPD Exacerbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patterns of Care Seeking
Number of subjects: 0
Study: 37966670

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: Active cancer
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: Lung or metastatic cancer
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: Brain, hematological or gastrointestinal cancer
Number of subjects: 4956
Study: 37966676

Group type: EXPERIMENTAL
Intervention: 12-hour empowerment self-defense (ESD) intervention
Number of subjects: 3263

Group type: COMPARATOR
Intervention: Standard of care (2-hour intervention)
Number of subjects: 3263
Study: 37966817

Group type: EXPERIMENTAL
Intervention: Tafamidis 80 mg
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 37966840

Group type: EXPERIMENTAL
Intervention: EPICC (Empowering Patients in Chronic Care)
Number of subjects: 248

Group type: COMPARATOR
Intervention: EUC (Enhanced Usual Care)
Number of subjects: 248
Study: 37966841

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 1174
Study: 37966877

Group type: EXPERIMENTAL
Intervention: Mobile health intervention 'Olitor' (app usage at least weekly for 3 months)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mobile health intervention 'Olitor'
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study: 37967050

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy customized for visual symptoms (MBCT-vision)
Number of subjects: 21
Study: 37967058

Group type: EXPERIMENTAL
Intervention: Door-to-door delivery of oral azithromycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fixed-point delivery of oral azithromycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Door-to-door delivery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fixed-point delivery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both delivery methods
Number of subjects: 80
Study: 37967136

Group type: EXPERIMENTAL
Intervention: AZD9574
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZD9574 + TMZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMZ
Number of subjects: 0
Study: 37967148

Group type: EXPERIMENTAL
Intervention: KCONVAC vaccine (2 doses, 28 days apart)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 37967228

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 23
Study: 37967326

Group type: EXPERIMENTAL
Intervention: 1-dose rVSVΔG-ZEBOV-GP
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study: 37967350

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study: 37967392

Group type: EXPERIMENTAL
Intervention: Restriction and Pressure to Eat
Number of subjects: 0
Study: 37967471

Group type: EXPERIMENTAL
Intervention: COVID-19 infection in ITP patients
Number of subjects: 1148
Study: 37967565

Group type: EXPERIMENTAL
Intervention: Psychoeducation (Parental Psychoeducation in CHD [PPeCHD]) and usual routines
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular practices (control group)
Number of subjects: 28
Study: 37967641

Group type: EXPERIMENTAL
Intervention: Pharmacist e-consult
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Social norming dashboards
Number of subjects: 466

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 466
Study: 37967828

Group type: EXPERIMENTAL
Intervention: Pancreatic quantitative sensory testing
Number of subjects: 0
Study: 37968000

Group type: EXPERIMENTAL
Intervention: Individual patient data meta-analysis (IPD-MA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing PSE prediction models
Number of subjects: 0
Study: 37968003

Group type: EXPERIMENTAL
Intervention: moderate-intensity aerobic physical activity for 150 min/week
Number of subjects: 130
Study: 37968012

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole intravenously daily while mechanically ventilated in the ICU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical placebo daily while mechanically ventilated in the ICU
Number of subjects: 0
Study: 37968015

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 2228

Group type: EXPERIMENTAL
Intervention: Resting tricuspid annular plane systolic excursion to systolic pulmonary artery pressure <0.7 mm/mm Hg
Number of subjects: 2228

Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure-cardiac output >5 mm Hg.min/L
Number of subjects: 2228
Study: 37968019

Group type: EXPERIMENTAL
Intervention: Invasive strategy involving early coronary angiography with immediate evaluation for revascularization and optimal medical therapy
Number of subjects: 457

Group type: COMPARATOR
Intervention: Conservative strategy (optimal medical therapy)
Number of subjects: 457
Study: 37968017

Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index (AHI)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Percentage of recording time with oxygen saturation <90% (T90)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: T90
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: T90 in non-CTD-associated PAH
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: T90 in CTD-associated PAH
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sleep-related hypoxia
Number of subjects: 186
Study: 37968125

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP target of 110 mmHg to <130 mmHg)
Number of subjects: 8511

Group type: COMPARATOR
Intervention: Standard treatment (SBP target of 130 mmHg to <150 mmHg)
Number of subjects: 8511

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 8511

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 8511
Study: 37968132

Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin (0.5 µg/kg, three times weekly)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 37968170

Group type: EXPERIMENTAL
Intervention: Kidney BEAM physical activity digital health intervention
Number of subjects: 340

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 340
Study: 37968194

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37968287

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) monitoring
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Arterial waveform-based monitoring (FloTrac-Vigileo)
Number of subjects: 1565
Study: 37968455

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers treatment
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Low alcohol consumption
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: High BPV
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 454
Study: 37968547

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tidal volume ventilation
Number of subjects: 0
Study: 37968668

Group type: EXPERIMENTAL
Intervention: MenSC therapy (bilateral intraovarian injection of menstrual blood-derived mesenchymal stromal cells)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MenSC therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 180
Study: 37968689

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 764

Group type: COMPARATOR
Intervention: Usual nutritional care
Number of subjects: 764
Study: 37968696

Group type: EXPERIMENTAL
Intervention: Post-biopsy anti-HER2 treatment
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: HER2-driven expression profile
Number of subjects: 700

Group type: COMPARATOR
Intervention: Prior anti-HER2 treatment
Number of subjects: 700
Study: 37968718

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 immunotherapy
Number of subjects: 0
Study: 37968738

Group type: EXPERIMENTAL
Intervention: Short-duration deep breathing (SDDB) + Conventional physiotherapy (CP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy (CP)
Number of subjects: 30
Study: 37968741

Group type: EXPERIMENTAL
Intervention: Two-dose AZI (biannual azithromycin-MDA)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Four-dose AZI (quarterly azithromycin-MDA)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1
Study: 37969014

Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide and Emtricitabine (TAF/FTC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37969298

Group type: EXPERIMENTAL
Intervention: Warming palpation (WP)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Warming ultrasonography-guided (WU)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Non-warming palpation (NP)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Non-warming ultrasonography-guided (NU)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Warming groups (WP + WU)
Number of subjects: 152
Study: 37969395

Group type: EXPERIMENTAL
Intervention: apatinib (375 mg, orally, once daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: apatinib (375 mg, orally, once daily) plus etoposide (50 mg, orally on days 1-14 of each 21-day cycle)
Number of subjects: 54
Study: 37969640

Group type: EXPERIMENTAL
Intervention: Endothelin receptor blocker (atrasentan)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Breast cancer patients (before chemotherapy)
Number of subjects: 28
Study: 37969646

Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 711

Group type: COMPARATOR
Intervention: hs-cTnT and hs-cTnI algorithms
Number of subjects: 711
Study: 37969655

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA) reported using the Godin-Shephard LTPA questionnaire
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Increased LTPA over the 3 months
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Insufficient LTPA according to PA guidelines
Number of subjects: 223
Study: 37969929

Group type: EXPERIMENTAL
Intervention: BAV
Number of subjects: 287

Group type: COMPARATOR
Intervention: TAV
Number of subjects: 287
Study: 37969936

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600 IU daily for 14-16 weeks)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo (1 capsule daily for 14-16 weeks)
Number of subjects: 498
Study: 37969958

Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 37970718

Group type: EXPERIMENTAL
Intervention: Gruticibart (anti-FXI mAb) 2 mg/kg administered through the venous catheter within 24 hours of placement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (noninterventional study)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gruticibart (anti-FXI mAb)
Number of subjects: 22
Study: 37971194

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily followed by venetoclax ramp-up to 400 mg daily for 22 additional 4-week cycles
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ibrutinib and venetoclax
Number of subjects: 45
Study: 37971361

Group type: EXPERIMENTAL
Intervention: Peripheral monocyte subset gating strategy using flow cytometry (FCM)
Number of subjects: 20
Study: 37971487

Group type: EXPERIMENTAL
Intervention: Aktiia Bracelet (cuffless optical BP device)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Austiatory measurements (reference method)
Number of subjects: 35
Study: 37971503

Group type: EXPERIMENTAL
Intervention: Early time-restricted carbohydrate consumption (eTRC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional dieting (control)
Number of subjects: 28
Study: 37971648

Group type: EXPERIMENTAL
Intervention: Paediatric Advanced Warning Score (PAWS) measured every 8 hours
Number of subjects: 2868
Study: 37971677

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment by Triage Clinicians (TC) and Study Team (ST) of medical students using a smartphone application.
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment by Triage Clinicians (TC) and geriED trained nurses (geriED-TN).
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment by Study Team (ST) of medical students and geriED trained nurses (geriED-TN).
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: CFS assessment at triage.
Number of subjects: 1349
Study: 37971692

Group type: EXPERIMENTAL
Intervention: ORZ-fortified canola oil
Number of subjects: 92

Group type: COMPARATOR
Intervention: Plain canola oil
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: All three groups
Number of subjects: 92
Study: 37971723

Group type: EXPERIMENTAL
Intervention: Brolucizumab, 6 mg, intravitreal injection every 4 weeks
Number of subjects: 517

Group type: COMPARATOR
Intervention: Aflibercept, 2 mg, intravitreal injection every 4 weeks
Number of subjects: 517
Study: 37971722

Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg intravenously) administered every 28 days for 4 doses
Number of subjects: 33
Study: 37971786

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37971800

Group type: EXPERIMENTAL
Intervention: SparkRx (self-guided, mobile app-based behavioral activation therapy)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Assessment-enhanced usual care (control)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: SparkRx
Number of subjects: 223
Study: 37971811

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure + Sertraline (PE + sertraline)
Number of subjects: 149
Study: 37971859

Group type: EXPERIMENTAL
Intervention: 38 sessions of neurofeedback (NF)
Number of subjects: 133
Study: 37971871

Group type: EXPERIMENTAL
Intervention: TV005
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 37972038

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vitrectomy with panretinal photocoagulation
Number of subjects: 204
Study: 37972091

Group type: EXPERIMENTAL
Intervention: High bed occupancy (90% of nationwide beds occupied)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Low bed occupancy (below 90% of nationwide beds occupied)
Number of subjects: 252
Study: 37972346

Group type: EXPERIMENTAL
Intervention: Detectable HPV ctDNA on dPCR at the end of CRT, 4-6 weeks post-CRT, and 3 months post-CRT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Undetectable HPV ctDNA
Number of subjects: 70
Study: 37972628

Group type: EXPERIMENTAL
Intervention: Non-invasive ultrasound therapy
Number of subjects: 40
Study: 37972659

Group type: EXPERIMENTAL
Intervention: FGFR inhibitors (FGFRi) therapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FGFR2-BICC1 fusion introduction in biliary tract cells
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of MEK inhibition with FGFRi
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of FGFRi and MEK inhibition in an in vivo animal model
Number of subjects: 17
Study: 37972723

Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tigatuzumab
Number of subjects: 0
Study: 37972895

Group type: EXPERIMENTAL
Intervention: Whole-food omnivorous meal (MEAT) containing 100 g lean ground beef, 0.45 g protein/kg body mass
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous whole-food vegan meal (PLANT)
Number of subjects: 16
Study: 37972929

Group type: EXPERIMENTAL
Intervention: Ankle block (30 ml of ropivacaine 0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sciatic nerve block at the popliteal crease (30 ml of ropivacaine 0.5% + saphenous nerve block)
Number of subjects: 60
Study: 37973184

Group type: EXPERIMENTAL
Intervention: Imaging of Myocardial α
Number of subjects: 0
Study: 37973206

Group type: EXPERIMENTAL
Intervention: 24/7 home palliative care (PC) service
Number of subjects: 2831

Group type: COMPARATOR
Intervention: Oncological population exposed to 24/7 PC
Number of subjects: 2831
Study: 37973340

Group type: EXPERIMENTAL
Intervention: Incentives for recent alcohol abstinence (group 2 and group 4)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Incentives for isoniazid adherence (group 3 and group 4)
Number of subjects: 680

Group type: COMPARATOR
Intervention: No incentives (group 1)
Number of subjects: 680

Group type: COMPARATOR
Intervention: No incentives for isoniazid adherence (group 1 and group 2)
Number of subjects: 680
Study: 37973342

Group type: EXPERIMENTAL
Intervention: Educational intervention for religious leaders incorporating cultural, theological, and medical teaching about family planning.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control communities (no intervention).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Educational intervention for religious leaders.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Communities during the COVID-19 pandemic.
Number of subjects: 24
Study: 37973472

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA1) - Local EA with two abdominal acupoints, administered daily for 4 days.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA2) - Local plus distal EA with twelve peripheral acupoints, administered daily for 4 days.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control - Conventional standard-of-care therapy for AP, no EA treatment.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combined EA (EA1 + EA2)
Number of subjects: 89
Study: 37973477

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (tE2) patches
Number of subjects: 251

Group type: COMPARATOR
Intervention: Luteinising hormone releasing hormone analogues (LHRHa)
Number of subjects: 251
Study: 37973545

Group type: EXPERIMENTAL
Intervention: Peanut, sesame and tree nut allergy assessment through skin testing, specific IgE measurements and oral food challenges.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Timing of the development of peanut, sesame and tree nut allergies in the first 3 years of life.
Number of subjects: 240
Study: 37973548

Group type: EXPERIMENTAL
Intervention: Active Sentry handpiece (AS)
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Non-AS handpiece
Number of subjects: 1432
Study: 37973659

Group type: COMPARATOR
Intervention: Raising Healthy Children (RHC) intervention
Number of subjects: 298